EBE58DF8-7300-4D3E-9672-A4E7ADF46113
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.7450722733245727
- age_years
- 58
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.630
- E2F_TARGETS+0.623
- OXIDATIVE_PHOSPHORYLATION+0.608
- MYC_TARGETS_V2+0.555
- G2M_CHECKPOINT+0.550
- DNA_REPAIR+0.518
- MTORC1_SIGNALING+0.516
- ANGIOGENESIS+0.509
- UNFOLDED_PROTEIN_RESPONSE+0.466
- PROTEIN_SECRETION+0.446
Top 10 suppressed
- KRAS_SIGNALING_DN-0.432
- PANCREAS_BETA_CELLS-0.196
- MYOGENESIS-0.144
- ESTROGEN_RESPONSE_EARLY-0.096
- SPERMATOGENESIS-0.077
- APICAL_SURFACE-0.048
- BILE_ACID_METABOLISM+0.018
- XENOBIOTIC_METABOLISM+0.042
- ESTROGEN_RESPONSE_LATE+0.062
- APICAL_JUNCTION+0.076
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.967 |
| 2 | 46061E4B-5256-42AD-BA9A-FBCEBE92B09A | — | — | 0.963 |
| 3 | 1B326CC6-3916-4D1D-A238-7B3C42F3E6C6 | — | — | 0.963 |
| 4 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.961 |
| 5 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.961 |
| 6 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.959 |
| 7 | 52F6F0A9-8D2D-49BC-9B49-E20E5E53561C | — | — | 0.956 |
| 8 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.956 |
| 9 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.956 |
| 10 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.956 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.630 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.623 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.608 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.555 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.518 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.516 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.509 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.466 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.446 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.432 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.432 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.397 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.397 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.386 | Inavolisib | — uncovered |
| APOPTOSIS | 0.382 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.364 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.346 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.343 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.339 | Idelalisib | — uncovered |